Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immucell Cp (ICCC)

Immucell Cp (ICCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,142
  • Shares Outstanding, K 7,751
  • Annual Sales, $ 17,470 K
  • Annual Income, $ -5,770 K
  • 60-Month Beta 0.59
  • Price/Sales 2.24
  • Price/Cash Flow N/A
  • Price/Book 1.57
Trade ICCC with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.99 +0.60%
on 04/09/24
5.44 -7.72%
on 03/28/24
+0.06 (+1.21%)
since 03/19/24
3-Month
4.83 +3.93%
on 02/05/24
5.54 -9.41%
on 01/30/24
-0.05 (-0.99%)
since 01/19/24
52-Week
4.26 +17.84%
on 05/12/23
6.05 -17.02%
on 06/13/23
+0.03 (+0.60%)
since 04/19/23

Most Recent Stories

More News
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET...

ICCC : 5.02 (-0.59%)
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®

PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...

ICCC : 5.02 (-0.59%)
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

PORTLAND, Maine, July 07, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...

ICCC : 5.02 (-0.59%)
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022

Q1 2022 Product Sales Increased 46% over Q1 2021...

ICCC : 5.02 (-0.59%)
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022

Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET...

ICCC : 5.02 (-0.59%)
UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation...

ICCC : 5.02 (-0.59%)
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that...

ICCC : 5.02 (-0.59%)
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022

PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...

ICCC : 5.02 (-0.59%)
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

Annual Product Sales for 2021 Increased 25% over 2020...

ICCC : 5.02 (-0.59%)
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET...

ICCC : 5.02 (-0.59%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM,...

See More

Key Turning Points

3rd Resistance Point 5.09
2nd Resistance Point 5.08
1st Resistance Point 5.06
Last Price 5.02
1st Support Level 5.03
2nd Support Level 5.02
3rd Support Level 5.01

See More

52-Week High 6.05
Fibonacci 61.8% 5.37
Fibonacci 50% 5.16
Last Price 5.02
Fibonacci 38.2% 4.94
52-Week Low 4.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar